[Hematopoietic Transplantation Outcomes in Patients with HLA-Identical, Haploidentical, and Unrelated Donors at a University Hospital in Chile].

Unlabelled: Allogeneic transplantation (HSCT) is a curative option for several hematological diseases. Our center has privileged the use of identical family donors (IFD) or haploidentical (HD) donors. However, the chances of finding family donors may be challenging in small families or unsuitable donors.

Geographic and Demographic Disparity in Firearm Injury: A 33-Year Retrospective Cohort Analysis of Florida Communities.

Background: Firearm violence in America has been declared a public health crisis. This study investigates variation in firearm injuries by county-level characteristics and intent of firearm use.

Study Design: The open-access FLHealthCHARTS was searched for firearm injuries from 1989-2022.

Alternative Magnification Devices for Microsurgical Training. Comparative analysis.

Aim: Determine if low-cost magnification devices (USB computer microscope, smartphone) enable the acquisition and maintenance of basic microsurgical skills by comparing skills learned using these devices against those learned using a surgical microscope. Determine whether skills acquired using these devices can be transferred to the surgical microscope.

Material And Methods: Twelve neurosurgical participants, ranging from faculty to postgraduate year-1 trainees, were randomly divided into three groups for training using a surgical microscope, smartphone, or USB microscope.

Monocytes generated by interleukin-6-treated human hematopoietic stem and progenitor cells secrete calprotectin that inhibits erythropoiesis.

Elevated circulating levels of calprotectin (CAL), the S100A8/A9 heterodimer, are biomarkers of severe systemic inflammation. Here, we investigate the effects of CAL on early human hematopoiesis. CAL demonstrates limited impact on gene expression in stem and progenitor cells, in contrast with interleukin-6 (IL6), which promotes the expression of the and genes in hematopoietic progenitors and the generation of monocytes that release CAL.

Hypomethylating agents for patients with VEXAS without myelodysplastic syndrome: Clinical outcome and longitudinal follow-up of vacuolization and UBA1 clonal dynamics.

VEXAS syndrome is a haemato-inflammatory disease caused by somatic UBA1 mutations and characterized by cytoplasmic vacuoles in myeloid and erythroid precursor cells. Although there is currently no standard treatment algorithm for VEXAS, patients are generally treated with anti-inflammatory therapies focused on symptom management, with only partial effectiveness. Hypomethylating agents (HMA) have shown promise in VEXAS patients with concomitant myelodysplastic syndrome (MDS), while the efficacy of HMA in VEXAS patients without MDS is largely unknown.